Pfizer drops early-stage asthma candidate
pharmafile | May 11, 2011 | News story | Research and Development |ย ย Pfizer, Rigel, asthmaย
Pfizer has returned the rights to a phase I asthma candidate to Rigel Pharmaceuticals.
San Francisco-based Rigel says Pfizer is giving up on R343 because of its decision to exit allergy and respiratory R&D. Nevertheless it is likely that Pfizer reassessed the drug as not having sufficient promise to continue its development.
R343 is an inhaled syk inhibitor for allergic asthma that recently completed several phase I clinical trials.
Rigel says initial results from phase I trials, which have not yet been published, show R343 to be well tolerated and with beneficial improvement in both the early and late phase asthmatic responses following an allergen challenge.
Andrew McConaghie
Related Content

1nhaler receives ยฃ1.5m in funding to develop new cardboard inhaler
1nhaler, a Scotland-based developer of drug delivery devices, has received ยฃ1.5m in seed funding for …
NICE recommends Pfizerโs new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21stย May 2025ย โย Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …






